WASHINGTON - An NIH survey of technology transfer agreements, spawned by the Scripps-Sandoz deal, apparently has not uncovered controversy of equal magnitude, according to findings summarized at a congressional hearing last week.

Outgoing NIH Director Bernadine Healy used the findings to support her contention that the pending agreement between Scripps Research Institute and Sandoz Pharmaceuticals Corp. is "aberrant" due to a number of factors, including its scale, duration, and restrictions placed on Scripps.

Guidelines in offing

By contrast, the NIH cited the research-support agreements entered into by its grantee institutions as